Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss (NCT06810544)
A Phase 1/2, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, and Preliminary Antitumor Activity of TNG456 Monotherapy and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
🩺 Plain-English Summary (8th-Grade Level)
This is a first in human study of TNG456 alone and in combination with abemaciclib in patients with advanced or metastatic solid tumors known to have an MTAP loss. The first part of the study is an open-label, dose escalation and the second part is an open label dose expansion in specific solid tumor types with a confirmed MTAP loss. The study drug, TNG456, is a selective PRMT5 inhibitor administered orally. The study is planned to treat up to 191 participants.
Who can join: Review the eligibility criteria below.
Location: Mayo Clinic Scottsdale — Scottsdale, Arizona
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (15 Sites)
- Mayo Clinic Scottsdale — Scottsdale, Arizona
- University of California, Irvine — Irvine, California
- University of California Los Angeles — Los Angeles, California
- University of California at San Francisco — San Francisco, California
- Sibley Memorial Hospital — Washington D.C., District of Columbia
- Mayo Clinic Jacksonville — Jacksonville, Florida
- Northwestern Memorial Hospital — Chicago, Illinois
- Dana Farber Cancer Institute — Boston, Massachusetts
- Mayo Clinic Cancer Center — Rochester, Minnesota
- NYU Langone Health — New York, New York
- Memorial Sloan Kettering Cancer Center — New York, New York
- Ohio State University Comprehensive Cancer Center — Columbus, Ohio
- MD Anderson Cancer Center — Houston, Texas
- University of Utah, Huntsman Cancer Institute — Salt Lake City, Utah
- NEXT Virginia — Fairfax, Virginia
📞 Contact the Study Coordinator
Phone: (857) 320-4899
Email: clinicaltrials@tangotx.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Non Small Cell Lung Cancer
- The Transitions Project: Supporting Adults During the Shift From Cancer Treatment to Surveillance — Boston, Massachusetts
- A Study of Lorlatinib in Combination With Ramucirumab in People With Lung Cancer — Middletown, New Jersey
- Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC — Beverly Hills, California
- Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer — Columbus, Georgia
- Assessment of Precision Irradiation in Early NSCLC and Interstitial Lung Disease — Edmonton, Alberta
- A Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast Cancer — Springdale, Arkansas
Explore by condition: All Non Small Cell Lung Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.